BetaShares Geared Australian Equity Fund (Hedge Fund)

GEAR

GEAR.AX was created on 2014-04-30 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 474.69m in AUM and 202 holdings. The Fund aims to provide investors with geared exposure to a diversified portfolio of Australian shares as simply as buying any share on the ASX. As the fund is internally geared, investors do not need to take out margin loans and do not have the possibility of margin calls in relation to their investment in the Fund.

Genesis Minerals Limited

GMD

Genesis Minerals Ltd. engages in the exploration and development of gold deposits in Western Australia. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-08-02. The principal activities of the Company are processing at Mt Morgans, exploration of its 100% owned tenement packages at Laverton and Leonora and pre-development activities at the Ulysses Gold Project. Mt Morgans comprises a portfolio of open pit and underground mineral resources, a 2.9 million tons per annum (Mtpa) conventional carbon-in-leach processing plant. The Leonora Gold Project is located 30 kilometers (km) south of Leonora and 200km north of Kalgoorlie, in the Eastern Goldfields of Western Australia. The Barimaia Gold Project is in the Murchison District of Western Australia, 10 Km southeast of the Mt Magnet Gold Mine. Its Leonora operations also include Gwalia underground mine, 1.4Mtpa Leonora mill, Tower Hill project, the Zoroastrian project, and the Aphrodite and Harbour Lights refractory projects. The firm also holds Bruno-Lewis and Raeside gold tenements in Western Australia.

Mesoblast Limited

MSB

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.

Zenith Minerals Limited

ZNC

Zenith Minerals Ltd. is engaged in the identification, exploration and development of base, industrial and precious metal deposits. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-05-29. The firm is focused on minerals containing lithium and related metals required for rechargeable lithium-ion batteries for electric vehicles and renewable energy storage. The company also has a portfolio of gold and base metal deposits located in Western Australia and Queensland. Its projects are Split Rocks Lithium-Tantalum Project, Waratah Well Lithium-Tantalum Project, Hayes Hill Lithium - Nickel Project, Split Rocks Gold Project, Red Mountain Gold-Silver Project and Earaheedy Zinc Project. The Split Rocks Project is located approximately 40 km south of the regional town of Marvel Loch in the Goldfields Region of Western Australia. The Waratah Well project is located over 20 km northwest of the regional town of Yalgoo in the Murchison Region of Western Australia. The Hayes Hill project consists of four granted exploration licenses in a highly mineral prospective corridor north of Norseman in Western Australia.

4Dmedical Limited

4DX

4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-08-07. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. The company initiated the commercial rollout of XV LVAS with I-MED Radiology Network (I-MED), which is a diagnostic imaging provider with approximately 250 clinics nationwide. The firm provides its lung imaging technology to other selected clinics across the I-MED network.